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Summary
 
The aim of this work was to decipher how graft-versus-host disease (GVHD) affects T cell pro-
duction and homeostasis. In GVHD
 
1
 
 mice, thymic output was decreased fourfold relative to
normal mice, but was sufficient to maintain a T cell repertoire with normal diversity in terms
of V
 
b
 
 usage. Lymphoid hypoplasia in GVHD
 
1
 
 mice was caused mainly by a lessened expan-
sion of the peripheral postthymic T cell compartment. In 5-bromo-2
 
9
 
-deoxyuridine pulse-chase
 
experiments, resident T cells in the spleen of GVHD
 
1
 
 mice showed a normal turnover rate (pro-
liferation and half-life). When transferred into thymectomized GVHD
 
2
 
 secondary hosts, T
cells from GVHD
 
1
 
 mice expanded normally. In contrast, normal T cells failed to expand when
injected into GVHD
 
1
 
 mice. Thus, the reduced size of the postthymic compartment in GVHD
 
1
 
mice was not due to an intrinsic lymphocyte defect, but to an extrinsic microenvironment ab-
normality. We suggest that this extrinsic anomaly is consistent with a reduced number of func-
tional peripheral T cell niches. Therefore, our results show that GVHD-associated T cell hypo-
plasia is largely caused by a perturbed homeostasis of the peripheral compartment. Furthermore,
they suggest that damage to the microenvironment of secondary lymphoid organs may represent
an heretofore unrecognized cause of acquired T cell hypoplasia.
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A
 
lthough GVHD causes damage to many recipient
organs, one of the most important hallmarks of this
disease is a profound defect in the development of donor-
derived T cells that is responsible for a long-lasting immu-
nodeficiency state (1–7). GVHD is initiated by host-reac-
tive T cells that produce copious amounts of cytokines and
cause direct cytotoxicity via Fas-, TNF-, and perforin-medi-
ated pathways (8–12). This antihost allogeneic attack, com-
monly referred to as acute GVHD, occurs during the first
few days/weeks after transplantation and is of limited time
duration (13) since donor-derived antihost T cells undergo
massive activation-induced cell death (Brochu, S., B. Rioux-
Massé, D.C. Roy, and C. Perreault, manuscript submitted
for publication). After the acute phase of GVHD has abated,
most recipients are left with a chronic immunodeficiency
state characterized by frequent opportunistic infections and
autoimmune manifestations; i.e., the so-called chronic phase
of GVHD (4, 13, 14). The immune deficiency found dur-
ing chronic GVHD mainly involves T cells, and is character-
ized by a severe lymphoid atrophy and inadequate responses
to both recall antigens and new epitopes (15–20). It re-
mains unclear how a time-limited antihost T cell response
can induce long lasting (commonly permanent) disturbances
in the differentiation and homeostasis of donor-derived
T cells.
During the last decade, studies using transgenic mice and
transplant chimeras have shed light on the intricacies of
T cell differentiation and homeostasis. It was shown that T cell
production can proceed along both thymic and extrathy-
mic pathways (21–23). This has been well ascertained by
investigations using mice transplanted with congeneic his-
tocompatible hematopoietic stem cell grafts. In young eu-
thymic recipients, T cell reconstitution is carried out by
donor hematopoietic progenitor cells that differentiate into
the host’s thymus (21, 23). In contrast, in athymic recipi-
ents, T cell reconstitution entirely depends on extrathymic
pathways and is influenced by the presence/absence of post
thymic T cells in the graft. When T lymphocytes are pre-
sent in the graft, their progeny is responsible for the repop-
ulation of host secondary lymphoid organs (21, 23). This
underscores the fact that mature T cells have a considerable
proliferation potential (up to 8 
 
3 
 
10
 
15
 
-fold) and can survive
long term in the absence of competing recent thymic emi-
grants (24–27). However, when the graft does not contain
T lymphocytes, reconstitution of peripheral T cell compart-
ments can only proceed through extrathymic maturation of 
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donor hematopoietic progenitors (22, 23, 28). In various
mouse models, extrathymic differentiation of hematopoie-
tic stem cells has been detected in the bone marrow (28,
29), the intestinal cryptopatches (30), the liver (22), and the
lymph nodes (31). The ability of these organs to replenish
and maintain lymph node and spleen T cell compartments
is considered to be much inferior to that of the thymus.
The number of peripheral CD4
 
1
 
 and CD8
 
1
 
 T lympho-
cytes is tightly regulated by poorly defined homeostatic
mechanisms that do not rely only on the cellular input into
the peripheral compartment (24, 32, 33). In support of this,
thymic output is not influenced by downstream alterations
in peripheral T cell pool size or CD4/CD8 ratio (34, 35)
and, furthermore, the size of peripheral T cell compart-
ments shows relatively modest variations when confronted
with a low/absent thymic output or with a major increase
in thymic output (e.g., hyperthymic mice and some trans-
genic models) (34–40). It thus seems that the number of
available T cell niches in secondary lymphoid organs deter-
mines the size of peripheral T cell compartments (38, 41).
The term niche designates an environment that provides
local conditions (such as expression of specific chemokines,
cytokines, and MHC molecules) required for T cells to
seed and survive long-term in the peripheral compartment
(41, 42). Recently, a number of evidences have been pre-
sented suggesting that resident dendritic cells represent fun-
damental constituents of the peripheral T cell niches (43–
46). Because of their abundant expression of MHC class I
and II molecules and their specific chemokine and cytokine
expression profile, dendritic cells seem to have a unique
ability to control the homing of postthymic T cells and to
provide the continuous TCR ligation required for the
survival of naïve and memory T cells in the periphery (33,
44, 47).
The goal of this work was to decipher the mechanisms
responsible for the GVHD-associated hypoplasia of periph-
eral T cell pools. Therefore, we addressed two questions.
Firstly, how does GVHD influence thymic and extrathy-
mic generation of donor-derived T lymphocytes? Knowing
that GVHD per se causes thymic dysfunction (17, 48, 49),
we wanted to quantify the impact of thymic lesions on thy-
mic output and determine whether GVHD also affected ex-
trathymic T cell production. Secondly, how does GVHD
influence T cell production, proliferation, and survival? In
otherwise normal subjects, the size of peripheral T cell com-
partments can be maintained even in the presence of a se-
verely decreased thymic output. Why, therefore, is chronic
GVHD associated with persistent lymphoid hypoplasia? Es-
tablishing how GVHD affects the size and repertoire of pe-
ripheral T cell compartments should be instrumental in un-
derstanding why patients with chronic GVHD present more
infections, autoimmune diseases, and neoplasia (14, 50–52).
Our results demonstrate that GVHD not only impairs thy-
mic production of new T cells, but also abrogates expan-
sion of mature T cell pools in secondary lymphoid organs.
Furthermore, they indicate that the defective expansion of
the peripheral postthymic T cell compartment in GVHD
 
1
 
mice is not due to an intrinsic T cell proliferative defect,
 
but rather to an extrinsic anomaly consistent with a restric-
tion in the number of functional peripheral T cell niches.
These findings allow for the development of a model in
which GVHD-associated lymphoid hypoplasia would rep-
resent a disease of soil (environment) rather than seed (T
cell). Accordingly, damage to the stroma of the thymus and
of secondary lymphoid organs inflicted during the acute
phase of GVHD would be responsible for a prolonged im-
pairment of the development of donor-derived T cells.
 
Materials and Methods
 
Mice. 
 
The following strains of mice were used: C57BL/6J
(H-2
 
b
 
) (Thy1.2
 
1
 
, Ly5.2
 
1
 
), B6.PL-
 
Thy1
 
a
 
/Cy (B6.PL; Thy1.1
 
1
 
,
Ly5.2
 
1
 
), B6.SJL-
 
Ptprc
 
a
 
Pep3
 
b
 
/BoyJ (Ly5
 
a
 
) (B6.SJL; Thy1.2
 
1
 
, Ly5.1
 
1
 
),
and A.BY-
 
H2
 
b
 
 H2-T18
 
b
 
/SnJ (ABY; Thy1.2
 
1
 
, Ly5.2
 
1
 
). Mice,
originally purchased from The Jackson Laboratory, were bred and
housed in specific pathogen-free conditions at the Guy-Bernier
Research Center according to the standards of the Canadian
Committee for Animal Protection. All mice used as primary cell
donors or irradiated recipients were between 8 and 20 wk of age.
For 5-bromo-2
 
9
 
-deoxyuridine (BrdU)
 
1
 
 incorporation studies, mice
were given sterile drinking water containing 0.8 mg/ml BrdU
(Sigma Chemical Co.), which was made fresh, changed daily, and
protected from light.
 
Thymectomy. 
 
At 4–8 wk of age, mice were anesthetized by
intraperitoneal injection of 75 mg/kg sodium pentobarbital
(Somnotol; MTC Pharmaceuticals). Thymectomy was performed
with a suction cannula introduced over the suprasternal notch.
Completeness of thymectomy was verified in each animal by vi-
sual inspection at the time of killing. Cell transplantation was per-
formed at least 2 wk after surgery.
 
Cell Transplantation and T Cell Depletion. 
 
Bone marrow cells
were T cell depleted and transplanted as previously described
(23). Recipient mice received 10 Gy total body irradiation on
day 0, the day of transplant. Bone marrow cells were obtained
from the tibias and femurs of donor mice and T cell depleted
with a specific anti-Thy1.2 mAb (5a-8; mouse IgG) or with a
rabbit anti–mouse T cells (Thy1) antiserum, both obtained from
Cedarlane Labs., and rabbit serum (Low-Tox-M rabbit comple-
ment; Cedarlane Labs.) as a source of complement. Efficacy of
depletion was assessed by flow cytometry. Spleen or axillary, cer-
vical, and inguinal LN cells were harvested and washed. The
number of T cells injected was determined by flow cytometry us-
ing an anti-Thy1.1 or anti-Thy1.2 Ab. Bone marrow and spleen
or LN cells were given as a single intravenous injection, via the
tail vein, in a volume of 0.5 ml.
 
mAbs.
 
The following Abs were obtained from PharMingen:
biotinylated anti-CD8
 
a
 
 (53-6.7; rat IgG2a) detected with Cy-
chrome™–streptavidin, FITC-conjugated anti–TCR-
 
a/b
 
 (H57-
597; hamster IgG), anti-V
 
b
 
3 (KJ25; hamster IgG), anti-V
 
b
 
5.1,2
(MR9-4; mouse IgG1), anti-V
 
b
 
6 (RR4-7; rat IgG2b), anti-V
 
b
 
7
(TR310; rat IgG2b), anti-V
 
b
 
8.1,2 (MR5-2; mouse IgG2a), anti-
V
 
b
 
9 (MR10-2; mouse IgG1), anti-V
 
b
 
10
 
b
 
 (B21.5; rat IgG2a),
anti-V
 
b
 
11 (RR3-15; rat IgG2b), anti-V
 
b
 
13 (MR12-3; mouse
IgG1), anti-V
 
b
 
14 (14-2; rat IgM), anti-V
 
b
 
17
 
a
 
 (KJ23; mouse
IgG2a), anti-CD45.1 (Ly5.1; 104; mouse IgG2a), anti-CD45.2
(Ly5.2; A20; mouse IgG2a); PE-conjugated anti-Thy1.2 (30-
H12; rat IgG2b), anti-Thy1.1 (OX-7, mouse IgG1,k), anti-
 
1
 
Abbreviation used in this paper:
 
 BrdU, 5-bromo-2
 
9
 
-deoxyuridine. 
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CD62L (MEL-14; rat IgG2a,k), anti–TCR-
 
g/d
 
 (GL3; hamster
IgG), and specific Cy-chrome™-conjugated anti-CD4 (RM4-5;
rat IgG2a), anti-CD8
 
a
 
 (53-6.7; rat IgG2a) Abs, and their isotypic
controls. PE-conjugated anti-CD4 (YTS 191.1, rat IgG2b), anti-
CD8
 
a
 
 (YTS 169.4, rat IgG2b) Abs and their isotypic controls
were purchased from Cedarlane Labs., and the FITC-conjugated
anti-BrdU Ab was purchased from Becton Dickinson.
 
Flow Cytometry.
 
Cell surface staining was performed as previ-
ously described (23). BrdU labeling was performed as described
by Tough and Sprent (27). In brief, after surface staining, cells
Figure 1. The influence of GVHD on T cell development in allogeneic chimeras. Irradiated euthymic (A and C) or thymectomized (B and D) A.BY
(Thy1.2, Ly5.2) recipients received a graft containing 107 T cell–depleted B6.PL (Thy1.1, Ly5.2) bone marrow cells (as a source of hematopoietic progeni-
tors) with or without mature T cells (0.4 or 1.6 3 106) harvested from the LNs of B6.SJL donors (Thy1.2, Ly5.1). Chimeras’ spleen cells were analyzed by
three-color staining on day 100 6 5 posttransplant. The origin of recipient T cells was determined according to their Thy1/Ly5 phenotype. Results are pre-
sented as the mean 6 SD (three to four mice per group). Note that the ordinate scale is different in A and B versus C and D. nd, not determined. 
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were resuspended in cold 0.15 M NaCl, fixed by dropwise addi-
tion of cold 95% ethanol, incubated for 30 min on ice, and washed
with PBS. The cells were then incubated with PBS containing
1% paraformaldehyde and 0.01% Tween 20 for 30 min, pelleted,
and then incubated for 30 min with 50 KU of DNase I (Sigma
Chemical Co.) in 0.15 M NaCl and 4.2 mM MgCl
 
2
 
, pH 5. After
washing, cells were incubated with FITC-conjugated anti-BrdU
for 30 min and washed. Cells were analyzed on a FACScalibur
 
®
 
using the CellQuest program or on a FACScan
 
®
 
 using the Lysis
II program (all from Becton Dickinson).
 
Results and Discussion
 
The Influence of GVHD on T Cell Development in Allogeneic
Chimeras.
 
Irradiated euthymic or thymectomized A.BY
(Thy1.2, Ly5.2) recipients received a graft containing B6.PL
(Thy1.1, Ly5.2) bone marrow cells (as a source of hemato-
poietic progenitors) with or without mature T cells harvested
from the LNs of B6.SJL donors (Thy1.2, Ly5.1). The origin
of recipient T cells was determined according to their Thy1/
 
Ly5 phenotype. Recipients were studied on day 100 after
transplant; i.e., after the allogeneic acute phase of GVHD was
terminated. We found that two factors affected the level of
T cell reconstitution: the presence/absence of a host thymus
and the presence/absence of GVHD (Fig. 1). Indeed, based on
the number of both CD4
 
1
 
 and CD8
 
1
 
 T cells found in the
spleen of day 100 chimeras, the following hierarchy was ob-
served (Fig. 1): thymus
 
1
 
 GVHD
 
2
 
 (group A) 
 
. 
 
thymus
 
2
 
GVHD
 
2
 
 (group B) 
 
. 
 
thymus
 
1
 
 GVHD
 
1
 
 (group C) 
 
.
 
thymus
 
2
 
 GVHD
 
1
 
 (group D). These results confirm that, in
thymectomized recipients of a T cell–depleted graft, some
extrathymic differentiation of donor hematopoietic progen-
itors may take place, but that this cannot compensate for
the absence of the classical thymic differentiation pathway
(group B versus A) (22, 23, 28, 29, 53). More importantly,
they show that, in terms of T cell reconstitution of second-
ary lymphoid organs, the impact of GVHD (groups C and
D) is even more deleterious than that caused by the mere
absence of thymus (group B).
Figure 2. Skewing of Vb usage by
CD41 and CD81 T cells in athymic
GVHD1 chimeras. Three-color stain-
ing was performed using Abs against
CD4 or CD8, Thy1.1 or Thy1.2,
and specific Vb elements. Chimeras
were studied on day 100 6 5. Results
are presented as the mean 6 SD
(three to four mice per group). 
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In GVHD
 
1
 
 euthymic recipients grafted with low or
high numbers of donor T cells (group C), the number of
spleen T cells was decreased 6–12-fold relative to recipients
without GVHD (group A). T cell hypoplasia was slightly
more severe when the number of grafted T cells was in-
creased from 0.4 to 1.6 
 
3 
 
10
 
6
 
. Interestingly, most T cells
found in euthymic GVHD
 
1
 
 recipients (group C) did not
derive from expansion of grafted postthymic T cells, but
rather from the donor hematopoietic stem cells. We could
ascertain that the vast majority of these T lymphocytes
originated from donor hematopoietic progenitors that had
differentiated in the GVHD
 
1
 
 thymus and not in extrathy-
mic sites, because their numbers were decreased eightfold
in athymic GVHD
 
1
 
 recipients (group D versus C).
In athymic hosts, the occurrence of GVHD (group D)
caused an extremely severe T cell hypoplasia with T cell
numbers decreased by fivefold compared with athymic
GVHD
 
2
 
 recipients (group B). Among the few T cells that
were found in athymic GVHD
 
1
 
 mice, 
 
z
 
55% were derived
from grafted mature T cells, while 
 
z
 
45% had the pheno-
type of donor hematopoietic stem cells and were likely de-
rived from the extrathymic differentiation of these progen-
itors. T cells derived from grafted postthymic T cells were
much less abundant (
 
z
 
14-fold) in athymic GVHD
 
1
 
 hosts
(group D) than what we previously observed in similarly
treated syngeneic (GVHD
 
2
 
) recipients (23). Two main
conclusions can be drawn from these results. First, GVHD
not only impairs reconstitution via the thymic pathway,
but also abrogates expansion of grafted postthymic T cells.
Second, although thymus function is impaired in GVHD
 
1
 
chimeras, intra-thymic maturation still represents the most
effective pathway for T cell reconstitution in these mice.
 
The TCR V
 
b
 
 Repertoire of GVHD
 
1
 
 Mice. 
 
Results from
Fig. 1 indicate that in GVHD
 
1
 
 mice, the ability of thymic-
independent pathways to restore peripheral T cell pools is
extremely poor and much inferior to that of the classical
thymic pathway. Besides these quantitative considerations,
we were interested in determining whether the different
origin of T lymphocytes in athymic versus euthymic GVHD
 
1
 
chimeras would have any impact on their V
 
b
 
 profile. This
question was addressed because a continuous thymic out-
put can contribute to the maintenance of T cell diversity,
whereas the repertoire of T cell pools that rely solely on the
expansion of postthymic T cells is more prone to skewing
after stochastic encounter with antigens (38, 54). Thus, we
evaluated by flow cytometry the TCR V
 
b
 
 profile of T cells
(Thy1.1
 
1
 
) that differentiated in the thymus of nonthymecto-
mized GVHD
 
1
 
 recipients, of (Thy1.2
 
1
 
) cells that originated
from the expansion of grafted mature T cells in athymic
GVHD
 
1
 
 recipients, and of age-matched A.BY controls.
In both controls and euthymic GVHD
 
1
 
 mice, the pro-
portion of CD4
 
1
 
 and CD8
 
1
 
 cells bearing various Vb ele-
ments was remarkably constant and, except for Vb111 cells,
showed very little variation from mouse to mouse (Fig. 2). In
contrast, considerable variability in the usage of Vb chains
was found in athymic GVHD1 mice (Fig. 2). Thus, among
CD81 lymphocytes, the percentage of cells expressing Vb5
or Vb6 elements was 14–16 and 7–7.5%, respectively, in
euthymic GVHD1 mice, but 4–20 and 2–14.5%, respec-
tively, in athymic GVHD1 mice. Analyses based on size
heterogeneity or on sequence of the CDR3 region will be
required to assess more precisely the diversity and clonality
of these T cell populations (55, 56). Nevertheless, our re-
sults indicate that the TCR repertoire of T cells derived
from the expansion of grafted mature T cells is subject to
dramatic skewing in athymic GVHD1 mice. The absence
of Vb skewing in euthymic GVHD1 mice suggest that,
even though their thymus is damaged, it has the ability to
maintain a Vb profile that is similar to that of age-matched
controls.
Survival of Euthymic Versus Thymectomized GVHD1 Recip-
ients.  To address the biological significance of the residual
thymus function detected in nonthymectomized GVHD1
mice, we followed up to day 95 posttransplant the survival
of mice from experimental groups presented in Fig. 1 (Fig.
3). No deaths were observed either in thymectomized or
nonthymectomized GVHD2 recipients. In contrast, the
Figure 3. The influence of GVHD on survival of euthymic and
thymectomized recipients. Irradiated thymectomized or sham thymecto-
mized A.BY recipients received a graft (C57BL/6) containing 107 bone
marrow cells with either no, 0.4 3 106, or 1.6 3 106 LN T cells (10–12
mice per group). Survival was assessed daily up to day 95. In GVHD1
mice transplanted with 0.4 or 1.6 3 106 donor T cells, the survival of
thymectomized recipients was inferior to that of nonthymectomized recipi-
ents (P , 0.05, Student’s t test).1334 GVHD and Lymphoid Hypoplasia
presence/absence of the thymus significantly influenced the
survival of GVHD1 mice. Indeed, during the 100-d observa-
tion period, death rates were greater in thymectomized than
in nonthymectomized hosts: 25 vs. 0% and 65 vs. 10% for
thymectomized versus nonthymectomized recipients grafted
with 0.4 and 1.6 3 106 donor T cells, respectively. Thus, at
least in mice housed under specific pathogen-free conditions,
the limited T cell reconstitution afforded by the GVHD1
thymus has a major impact on posttransplant survival.
Thymus Output in GVHD1 Mice. Having found that
practically all T cells found in day 100 GVHD1 mice de-
rived from intra-thymic differentiation of donor hemato-
poietic stem cells, we wanted to quantitatively assess the
thymic function of GVHD1 mice. Relative to normal mice,
thymus cellularity was decreased by 33–50% in GVHD1
mice transplanted with a low or high number of T cells
(Fig. 4 A). The proportion of immature double- versus sin-
gle-positive CD41 and CD81 thymocytes was similar in
GVHD1 versus normal thymi (Fig. 4 B). To get a better
appraisal of thymus function, we measured the rate of pro-
duction of recent thymic emigrants after in vivo BrdU la-
beling (27). Euthymic A.BY recipients of B6.PL bone mar-
row cells with or without 0.4 3 106 B6.SJL LN T cells
were given BrdU-supplemented drinking water for 21 d be-
ginning on day 70 posttransplant, and three-color flow cy-
tometry analyses were performed selectively on CD62L1 T
cells. For both the CD41 and the CD81 subsets, recent
thymic emigrants were defined as CD62L1BrdUlo cells.
The CD62L2 T cell subset contains antigen-experienced
activated/memory T cells, while the CD62L1 subset con-
tains practically all naïve T cells and some “revertant” anti-
gen-experienced T cells (27, 57). The intensity of BrdU
labeling provides a convenient way to distinguish recent
thymic emigrants (BrdUlo) from “older” peripheral T cells
(BrdUhi) that divide during the BrdU-labeling period. Low
BrdU labeling of recent thymic emigrants results from cold
Figure 4. The effect of GVHD on thymic cellularity and thymic output. (A) Thymic cellularity and (B) proportion of double- and single-positive thy-
mocytes in euthymic A.BY recipients of a B6.PL bone marrow graft supplemented with no, 0.4 3 106, or 1.6 3 106 B6.SJL LN T cells. Three mice per
group. (C) Accumulation of recent thymic emigrants (CD62L1/BrdUlo cells) in the spleen of normal A.BY mice, GVHD2 recipients, and GVHD1
hosts. All mice received BrdU-supplemented drinking water for 21 d, beginning on day 70 posttransplant in the case of GVHD2 and GVHD1 mice.
GVHD2 and GVHD1 mice were euthymic A.BY recipients transplanted with 107 B6.PL bone marrow cells supplemented with no (GVHD2) or 0.4 3
106 (GVHD1) B6.SJL LN T cells. The data show the values obtained for two mice per time point. (D) Percentage of CD62L1 elements that were BrdUlo
in the three groups presented in C.1335 Dulude et al.
target competition in the thymus (27). Indeed, high levels
of apoptosis with local breakdown of DNA, as found in the
thymus but not in secondary lymphoid organs, leads to
cold target competition for BrdU incorporation.
After administration of BrdU for 21 d, the total number
of recent thymic emigrants (CD41/CD62L1/BrdUlo and
CD81/CD62L1/BrdUlo) per spleen was fourfold lower in
GVHD1 hosts relative to normal mice and GVHD2 recip-
Figure 5. Peripheral T cells from GVHD1 mice have a normal rate of cell
division (BrdU incorporation). (A) Proportion of CD62L1 and CD62L2 cells
in the spleen of normal A.BY mice, GVHD2 recipients, and GVHD1 hosts.
(B) Kinetics of BrdU labeling of T cells in the three experimental groups. Mice
received BrdU-supplemented drinking water for 21 d as in Fig. 4. Results are
presented as the percentage of BrdU-labeled (BrdUlo and BrdUhi) elements in
four cell subsets: CD4/CD62L1, CD4/CD62L2, CD8/CD62L1, and CD8/
CD62L2. *BrdU labeling of CD8/CD62L2 elements could not be studied in
the A.BY control group because this cell subset is practically undetectable in
8-wk-old A.BY mice (A). Two to three mice per point. The intensity of
BrdU labeling of the various T cell subsets on day 21 is presented in Fig. 6.
Figure 6. Intensity of BrdU labeling of T cells from mice placed on
BrdU water for 21 d, and then on normal water for a further 54 d. The
intensity of BrdU labeling (negative, low, high) is presented as a function
of CD62L expression (negative or positive) for both the CD41 and
CD81 T cell subsets. Each result is representative of three experiments.1336 GVHD and Lymphoid Hypoplasia
ients (Fig. 4 C). Thus, thymus output in GVHD1 mice was
significantly decreased but not absent. Interestingly, for both
CD41 and CD81 T cells, the percentage of CD62L1 ele-
ments that were BrdUlo was similar in mice with or with-
out GVHD (Fig. 4 D). This suggests that the reduced size
of the CD62L1 compartment, which encompasses naïve
and revertant T cells, cannot be wholly ascribed to a de-
creased input of recent thymic emigrants. If this were the
case, as in senescent individuals, one would expect not only
the absolute number but also the proportion of BrdUlo ele-
ments among CD62L1 cells to be decreased (58).
Results presented in Fig. 1 showed that the mere ab-
sence of thymus (group B) does not entail the severe level
of lymphoid hypoplasia found in GVHD1 mice (groups C
and D). In addition, we found that the thymus of GVHD1
mice was still functional with a thymocyte production
equivalent to 25% that of 8-wk-old controls or 18-wk-old
GVHD2 recipients (Fig. 4, C and D). Such a level of thy-
mus export has been shown to be sufficient to sustain the
size of T cell compartments in secondary lymphoid organs
of otherwise normal senescent mice (39, 40). Thus, thymus
hypoplasia cannot be held solely responsible for GVHD-
associated T cell hypoplasia. These data point to the exist-
ence of other factors that perturb peripheral homeostasis of
T cell compartments in GVHD1 mice.
Kinetics of BrdU Labeling and Disappearance of BrdU-labeled
Peripheral T Cells in GVHD1 Mice. To evaluate the rate
of division of peripheral T cells, BrdU labeling was per-
formed for 21 d, as in the previous experiment. Results for
CD62L1 and CD62L2 subsets were analyzed separately be-
cause it has been shown that CD62L2 cells divide more
rapidly than CD62L1 cells (27), and the proportion of
CD62L1 versus CD62L2 T cells were different in our ex-
perimental groups (Fig. 5 A). Strikingly, the kinetics of
BrdU labeling was similar in GVHD2 recipients, GVHD1
hosts and normal controls (Fig. 5 B). This suggests that the
reduced size of the CD62L1 and CD62L2 peripheral com-
partments is not due to a proliferative defect of resident
T cells, otherwise the proportion of dividing (BrdU1) T cells
would have been decreased.
Since BrdU is not reused, it was possible to perform
pulse–chase experiments. Thus, after being placed on BrdU
water for 21 d, mice were transferred to normal water to
examine the rate of decay of BrdU-labeled cells up to day
75. This approach has been used notably to show that the
peripheral T cell lymphopenia of BB rats is caused by a
shortened survival of T cells associated with an increased
apoptotic death rate relative to WF rat controls (59). The
intensity of BrdU labeling in T cells from GVHD1 and
control mice on days 21 and 75 is depicted in Fig. 6. The
rate of disappearance of BrdU-labeled T cells was similar in
the three experimental groups so that, by day 75, the re-
maining proportion of BrdU-labeled cells was z20% in
normal mice, GVHD2 recipients, and GVHD1 hosts (Fig.
7). We deducted from the above BrdU-labeling experi-
ments that the failure of peripheral homeostatic mecha-
nisms to compensate for the moderate decrease in thymic
output (Fig. 4) and to prevent the severe T cell depletion in
GVHD1 mice (Fig. 1) could neither be ascribed to an im-
pairment of T cell proliferative activity (Fig. 5), nor to a
shortened half-life of BrdU-labeled cells (Fig. 7). These
findings suggest that the deficient expansion of the postthy-
mic T cell compartment in GVHD1 mice was not due to
an intrinsic lymphocyte defect but to an extrinsic microen-
Figure 7. Kinetics of disappearance of BrdU-labeled T cells in
GVHD2 and GVHD1 mice. Decline in percent BrdU labeling of T cells
after transferring mice to normal water for 54 d. The intensity of BrdU la-
beling on day 75 is presented in Fig. 6. Two to three mice per point.
*The fate of CD8/CD62L2 elements could not be studied in the A.BY
control group because this cell subset is practically undetectable in 8-wk-
old A.BY mice (compare Fig. 5 A).1337 Dulude et al.
vironment abnormality. This led us to raise the intriguing
possibility that the number of peripheral T cell niches
might be decreased in GVHD1 mice. This premise, ac-
cording to which T cell hypoplasia would represent a
problem of soil (environment) rather than seed (lympho-
cytes), entails two crucial corollaries: (a) T cells from GVHD1
mice should expand normally in normal mice, and (b) lym-
phoid hypoplasia of GVHD1 mice should not be corrected
by infusion of (host-tolerant) T cells from normal mice.
Normal Expansion of T Cells from GVHD1 Mice after
Adoptive Transfer into Normal Hosts.  To determine whether
T cells from GVHD1 mice would expand in normal mice,
we compared the expansion of T cells from GVHD1 mice
with that of normal T cells after injection in normal thy-
mectomized/irradiated recipients (with no defect in pe-
ripheral niches). Thus, thymectomized/irradiated A.BY or
B6.SJL recipients were transplanted with 2 3 106 Thy1.11
Ly5.21 T cells harvested from the spleen of nonthymecto-
mized GVHD1 mice (compare Fig. 1 C) and 107 T cell–
depleted C57BL/6 bone marrow cells. The expansion of
T cells from GVHD1 mice was compared with that of normal
T cells 30 d after injection (together with T cell–depleted
bone marrow cells) into thymectomized/irradiated syn-
geneic recipients (Fig. 8). In all recipients, the origin of
T lymphocytes could be determined according to their
Thy1/Ly5 phenotype. Strikingly, the level of T cell recon-
stitution found in syngeneic (B6.SJL) or allogeneic (A.BY)
secondary recipients of GVHD1 T cells was similar to that
of hosts repopulated with normal T cells (Fig. 8). The
numbers of T cells harvested from secondary recipients were
increased twofold relative to those in day 100 GVHD1
mice. This difference is impressive when one considers that
(a) the T cell reconstitution of normal secondary hosts was
achieved after only 30 d (versus 100 d in GVHD1 mice),
and (b) GVHD1 mice had a measurable thymic output,
whereas reconstitution of thymectomized secondary hosts
was achieved strictly by expansion of transplanted postthy-
mic T cells. Hence, T cells from GVHD1 mice expanded
normally when transferred to normal hosts. As suggested by
the studies presented in Fig. 5, this shows that the failure of
T cells to expand in GVHD1 mice is not due to an intrin-
sic T cell–proliferative defect.
Interestingly, the fact that normal reconstitution was
achieved not only in syngeneic (B6.SJL) but also in alloge-
neic (A.BY) secondary hosts indicates that T cells found
in the spleen of day 70 GVHD1 mice could not elicit
GVHD, and thus were purged of functional host-reactive
T cells. As these T cells had differentiated in the thymus of
the GVHD1 mice, this observation supports the concept
that, at least after the acute phase of GVHD, the thymus of
GVHD1 mice efficiently performs negative selection of
host-reactive thymocytes (60). Furthermore, the lack of an-
tihost alloreactive T cells in day 70 GVHD1 mice argues
against the possibility that a persistent GVHD activity per se
could be responsible, notably via production of some cyto-
kine(s), for the persistent T cell hypoplasia found in long-
term (day 100) chimeras.
Failure of Normal Postthymic T Cells to Restore the Size of
the Peripheral Pool in GVHD1 Mice.  We next evaluated
whether adoptive transfer of normal postthymic T cells
Figure 8. Expansion of T cells from GVHD1 mice
after adoptive transfer into normal hosts. Three-color
staining was performed on spleen cell suspensions using
Abs specific for CD4 or CD8, Ly5.1 or Ly5.2, and
Thy1.1 or Thy1.2. (A) Numbers of CD41 and CD81
T cells of B6.PL origin (Thy1.1, Ly5.2) found in the
spleen of day 100 nonthymectomized GVHD1 recipi-
ents (negative controls). (B) Numbers of CD41 and
CD81 T cells of B6.PL origin (Thy1.1, Ly5.2) found
in the spleen of irradiated/thymectomized B6.SJL or
A.BY secondary hosts, on day 30 after injection of 107
T cell–depleted C57BL/6 bone marrow cells 1 2 3
106 T cells harvested from the spleen of day 70
GVHD1 mice (test group). (C) Numbers of
Thy1.21Ly5.21 T cells found in the spleen of irradi-
ated/thymectomized B6.SJL or A.BY hosts, on day 30
after injection of 107 T cell–depleted B6.PL bone mar-
row cells 1 2 3 106 T cells harvested from the spleen
of normal syngeneic donors (A.BY for A.BY secondary
recipients, C57BL/6 for B6.SJL secondary recipients)
(positive controls). GVHD1 mice were prepared as in
Fig. 1 C (irradiation followed by transplantation of 107
B6.PL bone marrow cells 1 0.4 3 106 B6.SJL LN T
cells). Results are presented as the mean 6 SD (three
to four mice per group). *P , 0.05, **P , 0.005 rela-
tive with numbers of CD41 or CD81 T cells in
GVHD1 mice (Student’s t test). No significant differ-
ence was found between T cell numbers presented in B
and C.1338 GVHD and Lymphoid Hypoplasia
would correct the T cell lymphopenia of GVHD1 mice.
The fate of normal T cells after passive transfer to histo-
compatible recipients depends on the quantity of available
T cell niches. When the size of the peripheral T cell com-
partment is normal, such that few T cell niches are avail-
able, most donor T cells disappear soon after transfer (61).
In contrast, transfer of T cells to “T-less” recipients, in
which numerous empty niches are available, is followed by
the persistence of a large proportion of donor-derived T cells
and a considerable antigen-driven expansion of these cells,
which results in the restoration of the size of the peripheral
compartment (26, 62).
To obtain T cells of B6 origin that were tolerant to
A.BY antigens, normal irradiated A.BY mice were trans-
planted with 107 T cell–depleted C57BL/6 bone marrow
cells. 60 d later, a spleen cell suspension from these chime-
ras containing 5 3 106 Thy1.21Ly5.21 T cells (of C57BL/6
origin) was injected into day 60 GVHD1 secondary hosts,
and the fate of Thy1.21Ly5.21 T cells was assessed 40 d af-
ter transfer. Before transfer, no Thy1.21Ly5.21 cells were
present in GVHD1 secondary hosts that had been con-
structed by injection of 107 B6.PL bone marrow cells 1
0.4 3 106 B6.SJL LN T cells into irradiated nonthymecto-
mized A.BY hosts. As a positive control, the proliferative
potential of postthymic T cells transferred into secondary
hosts was evaluated in a group of irradiated/thymectomized
GVHD2 recipients. When transferred into GVHD2 sec-
ondary hosts, postthymic T cells showed a major expansion
(Fig. 9 C), whose magnitude was similar to what has been
reported after transfer into irradiated/thymectomized syn-
geneic recipients (23). In contrast, transfer of host-tolerant
C57BL/6 T cells did not increase the size of the peripheral
T cell pool of GVHD1 recipients (Fig. 9 B). Indeed, 40 d
after their transfer into GVHD1 secondary hosts, only trace
amounts of Thy1.21Ly5.21 T cells were recovered. Thus,
supply of postthymic T cells that had differentiated in a
normal GVHD2 thymus and possessed a normal prolifera-
tion potential had no influence on the size of the splenic
T cell pool in GVHD1 mice. Together with those presented
in Fig. 8, these results demonstrate that the perturbed ho-
meostasis of the peripheral T cell pool in GVHD1 mice is
not due to a lymphocyte intrinsic anomaly, but rather to a
failure of the peripheral environment to support the seed-
ing and/or expansion of postthymic T cells.
In conclusion, the results presented in this paper show
that both central and peripheral mechanisms contribute to
the long lasting T cell hypoplasia found in GVHD1 mice.
GVHD1 mice have a decreased thymic output, but this de-
fect cannot be held solely responsible for peripheral T cell
hypoplasia. The lack of reconstitution of normal peripheral
T cell compartments is largely accounted for by an inability
of postthymic T cells to expand in the secondary lymphoid
organs of GVHD1 hosts. Collectively, our results provide
convincing evidence that the failure of mature T cells to
expand in GVHD1 mice is not due to an intrinsic lympho-
cyte defect, but to an undefined abnormality of the lymphoid
microenvironment: (a) postthymic T cells from GVHD1 mice
expanded normally in syngeneic or allogeneic secondary
Figure 9. Adoptive transfer of normal host (A.BY)-tolerant T cells into
nonthymectomized GVHD1 mice and thymectomized GVHD2 recipients.
(A) Number of T cells in the spleen of day 100 GVHD1 mice. GVHD1 mice
were prepared as in Fig. 1 C (irradiation followed by transplantation of 107
B6.PL bone marrow cells 1 0.4 3 106 B6.SJL T cells). (B) Number of T cells
in the spleen of day 100 GVHD1 mice previously injected, on day 60, with
5 3 106 host-tolerant T cells of C57BL/6 (Thy1.2,Ly5.2) origin. (C) Number
of T cells in the spleen of thymectomized A.BY mice 40 d after irradiation and
injection of 107 T cell–depleted B6.SJL bone marrow cells 1 5 3 106 host-tol-
erant B6.PL T cells. Host (A.BY)-tolerant T cells used in B and C experiments
were obtained from the spleen of nonthymectomized A.BY hosts, 60 d after
irradiation and injection of T cell–depleted C57BL/6 or B6.PL bone marrow
cells. Results are presented as the mean 6 SD (three to four mice per group).1339 Dulude et al.
hosts, and (b) normal T cells failed to expand in GVHD1
mice.
Until it is better defined, we think that this microenvi-
ronment defect is most consistent with a decrease in the
number of functional peripheral T cell niches. As men-
tioned in the introduction, resident dendritic cells may rep-
resent the most crucial elements of these niches. Thus, the
possible influence of quantitative and/or qualitative (e.g.,
expression of MHC molecules, chemokines, cytokines)
dendritic cell defects on T cell homeostasis in GVHD de-
serves further investigation. To our knowledge, these ques-
tions have not been addressed in mouse models of GVHD.
However, according to the limited information available
from human studies, it is noteworthy that chronic GVHD
appears to be associated with a major decrease in the num-
bers of dendritic cells in the skin and secondary lymphoid
organs (63–65). Alternatively, we cannot discard the possi-
bility that the microenvironment defect epitomized herein
as a reduction of functional T cell niches could be related
to the presence of a toxic and/or absence of supportive sol-
uble factor produced by cells other than dendritic cells.
Nevertheless, two elements argue against some involve-
ment of an inhibitory T cell–derived cytokine: no GVHD-
inducing T cells were detected in our day 100 GVHD1
mice, and the defect was not transferred to secondary re-
cipients of T cells from GVHD1 mice (Fig. 8).
These considerations emphasize the need for a precise
definition of the peripheral T cell niches, whose number
likely dictates the size of peripheral T cell pools. Further-
more, it will be important to determine whether a similar
microenvironment defect could represent an unrecognized
cause of acquired immunodeficiency in other settings. For
example, damage to peripheral T cell niches could provide
a plausible explanation for the prolonged hypoplasia of sec-
ondary lymphoid organs observed after massive T cell re-
sponses (66, 67). Importantly, a loss of peripheral T cell
niches must not be considered irreversible a priori, and may
possibly be amenable to therapy. Indeed, recent studies in
RIP-LT transgenic mice have demonstrated that engi-
neered local release of lymphotoxin can trigger lymphoid
neogenesis characterized by the formation of well orga-
nized and functional “tertiary” lymphoid tissue (68, 69).
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